Press

Acarix is attending 2023 BIO CEO & Investor Conference in New York City

07 Feb

Acarix, a leader in innovative acoustic and AI-based cardiac diagnostics, will be attending for the first time the 25th annual BIO CEO & Investor Conference in New York City, February 6-9, 2023.

The BIO CEO & Investor Conference is recognized as a premier event for C-Suite executive leaders, investors and banking communities, focusing on established as well as emerging companies, publicly traded and select private companies delivering innovation in health care.

For more information contact:
Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46 730 770283, email [email protected] 
Christian Lindholm, CFO, phone +46 705 118333, email [email protected]

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor®System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, [email protected]) is Certified Advisor of Acarix. For more information, please visit www.acarix.com. 

Attachments
Acarix is attending 2023 BIO CEO & Investor Conference in New York City

Tags:
,
Newer Invitation to presentation of Acarix´s fourth quarter report
Back to list
Older Acarix is attending 2023 BIO CEO & Investor Conference

Related Posts